Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;55(1):103-111.
doi: 10.4143/crt.2022.264. Epub 2022 Jun 20.

Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015

Da Som Jeon  1 , Ho Cheol Kim  1 , Se Hee Kim  2 , Tae-Jung Kim  3 , Hong Kwan Kim  4 , Mi Hyung Moon  5 , Kyongmin Sarah Beck  6 , Yang-Gun Suh  7 , Changhoon Song  8 , Jin Seok Ahn  9 , Jeong Eun Lee  10 , Jeong Uk Lim  11 , Jae Hyun Jeon  12 , Kyu-Won Jung  13 , Chi Young Jung  14 , Jeong Su Cho  15 , Yoo-Duk Choi  16 , Seung-Sik Hwang  17 , Chang-Min Choi  1   18 ; Korean Association for Lung Cancer; Korea Central Cancer Registry
Affiliations

Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015

Da Som Jeon et al. Cancer Res Treat. 2023 Jan.

Abstract

Purpose: This study aimed to provide the clinical characteristics, prognostic factors, and 5-year relative survival rates of lung cancer diagnosed in 2015.

Materials and methods: The demographic risk factors of lung cancer were calculated using the KALC-R (Korean Association of Lung Cancer Registry) cohort in 2015, with survival follow-up until December 31, 2020. The 5-year relative survival rates were estimated using Ederer II methods, and the general population data used the death rate adjusted for sex and age published by the Korea Statistical Information Service from 2015 to 2020.

Results: We enrolled 2,657 patients with lung cancer who were diagnosed in South Korea in 2015. Of all patients, 2,098 (79.0%) were diagnosed with non-small cell lung cancer (NSCLC) and 345 (13.0%) were diagnosed with small cell lung cancer (SCLC), respectively. Old age, poor performance status, and advanced clinical stage were independent risk factors for both NSCLC and SCLC. In addition, the 5-year relative survival rate declined with advanced stage in both NSCLC (82%, 59%, 16%, 10% as the stage progressed) and SCLC (16%, 4% as the stage progressed). In patients with stage IV adenocarcinoma, the 5-year relative survival rate was higher in the presence of epidermal growth factor receptor (EGFR) mutation (19% vs. 11%) or anaplastic lymphoma kinase (ALK) translocation (38% vs. 11%).

Conclusion: In this Korean nationwide survey, the 5-year relative survival rates of NSCLC were 82% at stage I, 59% at stage II, 16% at stage III, and 10% at stage IV, and the 5-year relative survival rates of SCLC were 16% in cases with limited disease, and 4% in cases with extensive disease.

Keywords: Epidemiology; Korea; Lung neoplasms; Relative survival rate.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Figures

Fig. 1
Fig. 1
Overall survival in patients with non–small cell lung cancer (NSCLC), according to clinical stage.
Fig. 2
Fig. 2
Overall survival in patients with small cell lung cancer (SCLC), according to clinical stage. ED, extensive disease; LD, limited disease.
See this image and copyright information in PMC

References

    1. Park S, Choi CM, Hwang SS, Choi YL, Kim HY, Kim YC, et al. Lung cancer in Korea. J Thorac Oncol. 2021;16:1988–93. - PubMed
    1. Hong S, Won YJ, Lee JJ, Jung KW, Kong HJ, Im JS, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2018. Cancer Res Treat. 2021;53:301–15. - PMC - PubMed
    1. Bar J, Urban D, Amit U, Appel S, Onn A, Margalit O, et al. Long-term survival of patients with metastatic non-small-cell lung cancer over five decades. J Oncol. 2021;2021:7836264. - PMC - PubMed
    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. - PubMed
    1. National Cancer Institute . SEER*Stat Database. Bethesda, MD: National Cancer Institute; 2021. Surveillance, Epidemiology, and End Results program.